Pipeline

Project family

Project

Status

Concept

Discovery

Pre-clinical

Respiratory Gas Transport System

NanOX 4 Kidney

In progress
  • Concept
  • Discovery
  • Pre-clinical

NanOX Recovery Box

In progress
  • Concept
  • Discovery
  • Pre-clinical

NanOX 4 Liver

Planned
  • Concept
  • Discovery
  • Pre-clinical

Blood Substitute – Humans

In progress, Completed
  • Concept
  • Discovery
  • Pre-clinical

Blood Substitute -Veterinary

Planned
  • Concept
  • Discovery
  • Pre-clinical

Polysaccharide Nanoparticle Platform

PolEpi

In progress
  • Concept
  • Discovery
  • Pre-clinical

Projects Based on Polysaccharide Nanoparticles

Planned
  • Concept
  • Discovery
  • Pre-clinical

Conjugates of dextran nanoparticles

TBA

In progress
  • Concept
  • Discovery
  • Pre-clinical

Radiotherapeutics

TBA

suspended
  • Concept
  • Discovery
  • Pre-clinical

Respiratory Gas Transport System

  • Based on a new method of nanoformulation of perfluorocarbons.
  • Perfluorocarbons allow for high concentrations of oxygen and carbon dioxide in liquids.
  • Thanks to the innovative manufacturing method, nanoparticles maintain a stable distribution once dissolved in the liquid.
  • This can be used in various applications, particularly in replacing the function of red blood cells

 

NanOX System - A Breakthrough in Transplantology

  • The NanOX system is the first complete solution on the market dedicated to warm kidney perfusion before transplantation.
  • It allows for keeping the kidney alive outside the body, supporting metabolic processes.
  • It enables the use of organs with higher risk, particularly from donors after circulatory arrest (DCD).
  • It doubles the potential transplant market, reducing healthcare and social costs for long-term dialysis patients.
  • It consists of the NanOX 4 Kidney perfusion fluid, based on our respiratory gas transfer technology, the NanOX Recovery Box perfusion device, and a single-use perfusion kit.

NanOX System includes:

NanOX 4 Kidney Perfusion Fluid

Successful Autotransplantation

After a 30-minute ischemia simulation, a pig kidney was removed and subjected to a 12-hour ex vivo perfusion at 25°C using the NanOX fluid and device, followed by a successful autotransplantation back into the donor. A 14-day observation period ended successfully.

147 Hours of Ex-Vivo Storage

We achieved a breakthrough in organ storage research, maintaining an organ in a viable state outside the body for 147 hours – longer than any existing solution on the market.

 

NanOX 4 Kidney Perfusion Device

  • Defined fluid temperature range from 4°C to 37°C
  • Circulation condition simulation
  • Continuous data registration
  • Emergency power supply
  • Development platform for additional organs

Temporary Blood Substitute

  • NanoGroup is developing a new version of a temporary blood substitute.
  • Our developed nano-emulsion solves challenges that have been faced by perfluorocarbon-based products.
  • This is one of the largest unmet medical needs and a project with the potential to transform emergency medicine.

 

 

 

 

 

Targeted Polysaccharide Nanoparticles

We possess proprietary, widely patented technology for the production and integration of polysaccharide nanoparticles.

 

Our polysaccharide nanoparticles utilize two targeting mechanisms:
  1. Drug Release Based on Intracellular pH Level – Nanoparticles enter the cell through endosomes. As a result of the low pH in the endosome, the bond breaks and the active substance is released.
  2. EPR Effect (Enhanced Permeability and Retention) – The rapid growth of tumor cells requires increased blood supply, resulting in greater permeability of blood vessels. Nanoparticles sized 100-200nm have a higher chance of reaching cancer cells.

 

 

Vehicle for Nanoformulation of Already Approved Drugs with Proven Effectiveness
This allows for improving their efficiency and safety.

 

FLEXIBILITY

Enables quick initiation of new projects, leading to the creation of derivative patents based on the core technology.

LIMITED RISK

Uses known and well-researched active substances with established therapeutic profiles and side effects, reducing developmental risks.

REPEATABILITY OF THE PROJECT

The polysaccharide nanoparticle technology accelerates project execution by leveraging the effects of previous studies.

STRONG SCIENTIFIC FOUNDATION

Research conducted in international centers forms the foundation for derivative projects.

Innovative Dextran-Based Conjugates for Targeted Cancer Therapy

  • The project aims to enhance targeting efficiency through the use of dextran, a water-soluble, biocompatible polysaccharide with a three-dimensional structure and high loading capacity for drugs and targeting agents.
  • Currently, research is underway on conjugation technology. Upon completion, specific therapeutic targets will be selected.
pp-thumbnail